WOBURN, Mass.--(BUSINESS WIRE)--Courtagen Life Sciences, Inc., a commercial-stage, innovative molecular information company that sells proprietary genomic diagnostic and drug metabolism assays for pediatric neurology disorders, announced today the appointment of Thomas Fairfield to the company’s Board of Directors.
“Tom has a wealth of legal, M&A, and operating experience,” states Brian McKernan, Chief Executive Officer of Courtagen. “We look forward to adding Tom’s valuable perspectives to our Board of Directors.”
Mr. Fairfield has served as Chief Operating Officer and a Director of WMIH Corp. since May 2015. Prior to joining WMIH, Mr. Fairfield was Executive Vice President of Capmark Financial Group Inc. He joined Capmark in March 2006 and served in various roles, including Chief Operating Officer, Executive Vice President, General Counsel, and Secretary. Prior to his tenure at Capmark, Mr. Fairfield practiced law for more than 20 years at several prominent international law firms, where his practice focused on general corporate and securities law, mergers and acquisitions, corporate finance, and financial services. He has been a Director at Capmark since September 2011 and previously served as a Director at The Cash Store Financial Services Inc. Mr. Fairfield has a Juris Doctorate degree from Georgetown University Law Center and a B.S.F.S. from Georgetown University. He is admitted to the bar of the states of Connecticut, Pennsylvania, New York, and the District of Columbia, and is a Member of the American Bar Association and the National Association of Stock Plan Professionals.
“I have been an investor in Courtagen since the early days, and believe in the team and the business prospects,” Thomas Fairfield responded. “I am pleased to join the Board of Directors of Courtagen to assist with the exciting new opportunities.”
About Courtagen Life Sciences, Inc.
Courtagen is a privately held life sciences and molecular information company that converts genomic data into actionable clinical information for the diagnosis of critical pediatric neurological and metabolic disorders. Specifically, Courtagen focuses on mitochondrial disorders, epilepsy, and intellectual disability, including autism spectrum disorders. Courtagen’s state-of-the-art Next-Generation Sequencing clinical laboratory integrates genotype, phenotype, and disease mechanism data using cloud-based computing and custom analytical methods to provide the most comprehensive results for clinicians, patients, and their families to better understand and treat their disease. More information can be found at www.courtagen.com.
